Application of serum protein marker combination to colorectal cancer screening, diagnosis and treatment

Abstract

The invention belongs to the technical field of molecular biology and clinical detection, and relates to a protein combination, wherein the protein combination is selected from any two or three or four or five or six of CA19-9, CEA, HGF, IP-10, MIP-1beta and SDF-1alpha. The invention further relates to a ligand combination specifically bound with proteins in the protein combination, and application of the protein combination or the ligand combination to preparation of a kit for colorectal cancer screening, auxiliary diagnosis, treatment monitoring and prognosis judging. A serum protein markercombination can be used for colorectal cancer screening, auxiliary diagnosis, treatment monitoring and prognosis judging and particularly used for early colorectal cancer screening and auxiliary diagnosis, and the sensitivity of the serum protein marker combination is superior to that of a single protein marker and commonly used clinical serum markers CA19-9 and CEA in detecting.

Description

technical field [0001] The invention belongs to the technical field of molecular biology and clinical detection, in particular, it relates to a marker combination comprising six proteins selected from CA19-9, CEA, HGF, IP-10, MIP-1β and SDF-1α, and the marker Application of the compound combination in preparation of serum marker kits for colorectal screening, auxiliary diagnosis, treatment monitoring and prognosis judgment. Background technique [0002] Colorectal cancer is one of the most common malignant tumors in the world today, posing a great threat to human health and life. In my country, according to the latest data from the National Cancer Center, there were 331,300 new cases of colorectal cancer in China in 2012, with an incidence rate of 24.47 / 10 6 ;Death cases were 159,300, and the death rate was 11.77 / 10 6 , its morbidity and mortality rank fourth and fifth respectively. Most patients are already in the advanced stage when they are diagnosed. The 5-year surviv...

AI Technical Summary

Problems solved by technology

[0004] Fecal occult blood test (FOBT) is currently a simple and economical screening method, but its sensitivity is low, it is not suitable for non-bleeding tumor patients, and the compliance and efficiency of census are still low, resulting in a large number of results. Missed diagnosis of early rectal cancer patients

Currently, the gold standard for the diagnosis of colorectal cancer is biopsy and histopathological examination of lesion tissue under fiberoptic colonoscopy, but it is difficult to make an accurate judgment on the degree of tumor canceration solely by local biopsy pathological tissue, and it is easy to cause missed diagnosis of early canceration of adenoma , and due to its invasiveness and price, it is difficult to be widely used in population screening

[0005] Currently, common serum markers for colorectal cancer include carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA19-9), etc., but the sensitivity and specificity of these tumor markers are limited.

Images